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ABSTRACT
While considerable attention has been focused on
understanding the myriad of ethical analysis in
international research in low and middle income
countries, new issues always arise that have not been
anticipated in guidelines or studied extensively. The
disruption of medical care arising as a direct result of
political actions, including strikes, postelection violence
and related activities, is one such issue that leaves
physician-researchers struggling to manage often
conﬂicting professional responsibilities. This paper
discusses the ethical conﬂicts that arise for physician-
researchers, particularly when disruption threatens the
completion of a study or completion is possible but at
the expense of not addressing unmet medical needs of
patients. We review three pragmatic strategies and the
ethical issues arising from each: not starting research,
stopping research that has already started, and
continuing research already initiated. We argue that
during episodes of medical care disruption, research that
has been started can be continued only if the ethical
standards imposed at the beginning of the study can
continue to be met; however, studies that have been
approved but not yet started should not begin until the
disruption has ended and ethical standards can again be
assured.
INTRODUCTION
Ethical analysis of international research has long
focused on issues arising throughout the life-cycle
of research, including traditional categories of
design, conduct, informed consent, risk-beneﬁt
assessment and dissemination of ﬁndings.1–3
Principles for international collaborative research
recommend local institutional review boards to
provide independent review, approval and oversight
of international research. Informed consent guide-
lines have tackled questions regarding the conﬂict
between respect for culture and respect for
persons, language barriers and cultural scepticism
for signing documents.1 2 Moreover, discussions
regarding appropriate standards of care for research
in developing countries have been addressed.3
However, there is considerably less ethical analysis
undertaken about research challenges in environ-
mental conditions that were not anticipated in
international guidelines. One of these is the condi-
tion of healthcare service disruption (referred to
hereafter as ‘medical’ disruption) where it has a
follow-on effect on the capacity to conduct
research.
Causes of medical disruption vary from natural
disasters to labour actions, from tsunamis to strikes.
Whether caused by human action or Mother
Nature, all types of medical disruption can impact
physician-researcher responsibilities. Unlike disrup-
tions in care caused by tsunamis, earthquakes or
tornadoes,4 5 we focus here on disruptions caused
by the actions of people. These disruptions make it
difﬁcult, sometimes impossible to care for patients;
and as we emphasise, there is an underappreciated
impact on the conduct of research. As resources are
stretched, decisions about whether to initiate
research or suspend research already underway, and
how to balance many conﬂicting obligations and
responsibilities take on a different meaning for host
country physician-researchers and for their collab-
orating colleagues from other countries.
We are particularly mindful of the ethical issues
arising from research in diverse settings given our
involvement in the two-decade long partnership
between Indiana University and Moi University in
Eldoret, Kenya called The Academic Model
Providing Access to Healthcare (AMPATH).6
AMPATH researchers work together to prioritise
health problems, determine the value of research
proposals, conduct studies, disseminate results and
apply the results to improve local health pro-
blems.7 8 We discuss ethical concerns that arise
from our experience with episodes of medical dis-
ruption, particularly when disruption threatens the
completion of research itself or completion is pos-
sible but at the expense of not addressing unmet
medical needs of patients.
Some work has already been done to unpack
these issues. For example, in recognition of the
importance of conducting research in the context
of humanitarian emergencies, Médecins Sans
Frontières uses a specialised ethics review proced-
ure to handle protocols of this type.9 Recently,
WHO and the Nigerian Health Ethics Research
Committee have developed positions on the use of
non-validated treatments in response to the Ebola
epidemic.10 11 We will discuss ethical issues related
to research and clinical care for consideration from
our experience during episodes of medical care dis-
ruption in Kenya.
MEDICAL DISRUPTION IN WESTERN KENYA: A
CASE STUDY IN RESEARCH RESPONSIBILITIES
In recent years, the AMPATH programme has
experienced several instances of medical disruption.
In 2007, postelection violence in Kenya erupted
after a disputed presidential election, resulting in
the deaths of more than 1200 people, injuring
many more, and displacing at least 300 000 people,
placing a huge burden on the medical
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community.12 In December 2011, September 2012, December
2013 and January 2015, national physicians’ and nursing strikes
took place in Kenya, which involved demands for increased
wages and increased allocation of the government’s budget
towards healthcare.13
During the postelection violence, rampant ethnic violence
made it unsafe for patients and staff to leave their homes.14
Vreeman et al14 describe some of these experiences: “Families
felt trapped…Because it was so life-threatening for them to go
on the roads and try to get to clinic.” Lack of public transporta-
tion, roadblocks and closure of businesses led to lack of
resources and difﬁculty for staff and patients to get to the hos-
pital. On top of all of these challenges, the horriﬁc terror and
stress of seeing neighbours murdered and colleagues’ homes
burn provided an overwhelming burden to the community.
On a much lesser scale, the medical strikes also created undue
stress for patients. Most patients do not have access to other
viable options for healthcare and often felt caught in the middle
between governments and healthcare providers. Additionally,
these political actions often result in outbreaks of violence.
During one of the strikes, police used tear gas throughout the
hospital and clinics.15 This not only made it more difﬁcult for
staff to work, but also created an unsafe environment for
already sick patients. Often these strikes result from dangerously
low supplies and medications. With the added missing resource
of medical staff, meeting patient care needs becomes extremely
difﬁcult.
As seen in these events in Kenya, medical disruptions can
vary in duration, cause and impact on patient care. Duration of
disruptions can vary from minutes or days to months or even
years. Knowing that these medical disruptions affect patient care
then leads us to consider the impact on research and the ethical
responsibilities of physician-researchers. Variations in the types
of disruption in care will inﬂuence ethical responsibilities of
healthcare providers to provide standard of care. As medical dis-
ruptions can vary in duration and impact, one can begin to envi-
sion several possible scenarios that can result in impact on a
healthcare provider’s obligation to provide standard of care. For
example, a short-term, minor disruption will likely have virtu-
ally no impact on the ethical responsibilities of physicians to
continue to provide the standard of care of that location.
However, a long-term, major disruption would be expected to
have signiﬁcant impact on the ability of physicians to fulﬁl their
ethical responsibilities to provide the standard of care.
While the impact on patient care caused by these political
events was well documented, less was known about the impact
on research. How might medical disruptions inﬂuence physi-
cians as researchers, particularly those that impact patients’
access to care or ability to obtain local standard of care? These
episodes of medical disruption cause signiﬁcant pause for
physician-researchers regarding how to proceed with research.
CONFLICT IN RESEARCH RESPONSIBILITY
In international collaborative research, physician-researchers
often have to balance clinical duties and research responsibil-
ities. In many low income and middle income countries, the
environment in which healthcare is delivered and research is
conducted is often one and the same. This is often the case in
resource-constrained settings where shortages of healthcare pro-
viders or limited access to care leave physician-researchers to
serve in both roles, making these ethical responsibilities difﬁcult
to separate.16 In times of medical care disruption, balancing
these roles appropriately can become very difﬁcult. With local
physician shortages, the physician-researcher often may be the
only physician a patient will see. With demanding clinical needs
and responsibilities, one can expect that during circumstances of
medical care disruption host and visiting physician-researchers
struggle with how to proceed with research.
Physician-researchers who serve in clinical and research roles
may feel pulled to more clinical responsibilities to meet those
needs, making it difﬁcult to fulﬁl research responsibilities.
Physician-researchers with primary research responsibilities may
also be pushed to take on clinical duties to meet needs of
patients who now have limited access to care.
The risks to research that we consider balancing in this discus-
sion primarily surround the duty to care, which is especially
strong where relationships between patient-participants and
physician-researchers already exist. Disruptions often result in
limited resources and personnel, which can lead to difﬁculty
with resource prioritisation for care versus research as well as
difﬁculty adhering to protocols. Additionally, in light of political
disruptions affecting healthcare, patients may be particularly
prone to issues of trust and exploitation as already inﬂuenced
by political agendas that must be taken into consideration when
asking to participate in research. It is important for these inter-
national collaborative research partnerships to avoid exploit-
ation in these difﬁcult situations by working in solidarity,
engaging community members and fostering development of
these healthcare systems when making decisions regarding con-
tinuation of research.17 With this in mind, we review three
general arguments for not starting research, stopping research
that has already started and continuing research.
ARGUMENT FOR NOT STARTING RESEARCH
It may seem intuitively obvious that during times when political
unrest affects access to medical care clinical research should not
be started. These political disruptions create risk to the public
generally and can prevent timely delivery of resources, limited
access to trained personnel, and increased stresses for patients
and clinicians.8 When disruptions turn dangerous, it is easy to
see how the ﬁrst order of business is to care for patients in
need, and not research subjects in studies.
Additionally, the ethical ground is less secure for research par-
ticipants. It is an accepted principle of research ethics that
research participants should not be exposed to unreasonable
risks, especially when there is no prospect of beneﬁt. Typically,
this balance is focused on risk and potential beneﬁt within the
study itself, but it would be naïve to exclude the risks to subjects
from political disruption since all research participants would be
exposed to them. In a high-risk environment where medical ser-
vices are needed and otherwise unavailable, there is an increased
risk to autonomy as patients may be more susceptible to joining
research as their only way to access care despite being well
informed.
Moreover, disruption of service dramatically increases the
likelihood of incomplete or compromised data, loss of con-
trolled conditions and introduction of confounding variables
into the ﬁnal analysis, diminishing the possibility of answering
the proposed research question. Since the beneﬁts of research
are often to science and society as a whole rather than to the
individual, beneﬁt from the study is also diminished. Also, since
no researcher-participant relationship has formed, there are no
expectations of participants for beginning or continuation.
Therefore, if the decision to start a new project increases the
likelihood that current patients will be worse off because
resources may be diverted from their care, then the ethical justi-
ﬁcation for starting research is difﬁcult to make. While research
has the potential to beneﬁt the health of populations, the risks
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overall are too high to start research during medical care disrup-
tion. The prudent course is to wait until after resolution of
these episodes when ethical standards can be met, the safety
of patients and research subjects assured, and the likelihood of
completing a study is maximised.
ARGUMENT FOR STOPPING RESEARCH ALREADY BEGUN
It may be ethically more expedient not to start a study but is
there an ethically relevant distinction within clinical research
ethics between stopping something underway and not starting?
We think there is. At a minimum, to stop a study already under-
way will involve the dashing of certain expectations and com-
mitments that not starting does not. Investigators expect studies
to be seen to their conclusions, research ethics committees give
their approval to studies expecting them to be completed,
funding bodies support ﬁnished rather than unﬁnished studies,
and patients entering a study have made certain commitments
to themselves, science, and others. Of course, under some cir-
cumstances studies should be stopped for legitimate reasons.
Studies determined to have perturbed equipoise sufﬁciently
should be stopped by Data Safety and Monitoring Boards, as
should studies that have been found to be non-compliant with
federal regulations.18
When relevant country-speciﬁc guidelines and regulations are
ambiguous or silent on this issue, researchers face a difﬁcult
decision and may seek input from review boards or other
experts in such matters.19 When the disruption is from a natural
disaster, the same public safety reasons that support not starting
a study would also militate against continuing. When research
disruption is from a ‘political’ situation, similar considerations
apply: where the disruption creates an immediate public health
risk, as occurred during the 2007 Kenyan election violence,
studies underway could sensibly be stopped. But what about dis-
ruptions caused by peaceful labour action? Here the argument
for continuing a study is stronger where physician-researchers
may still be able to carry out their duties, making continuing
research possible as compared with violent protests. However,
where the disruption targets healthcare facilities, preventing the
very clinicians who are also researchers from working, the cap-
acity to continue studies is substantially lessened.
Physician-researchers have ethical obligations to ensure care
for their patients.20 21 This obligation applies whether one is in
a trauma centre in Boston or an outpatient clinic in Burnt
Forest, Kenya. The Declaration of Helsinki makes several state-
ments on this issue in its introduction, including ‘the duty to
promote and safeguard the health of patients’ along with ‘the
well-being of the individual research subject must take prece-
dence over all other interests’.22 Therefore, if clinical care is not
being provided and a trade-off in providing care over research is
required, it is permissible to stop research until ethical standards
can once again be met. This responsibility to ensure care is
made particularly strong where research has already begun and
a relationship already exists between the patient and physician-
researcher. In the case of a study that holds out the prospect of
beneﬁt to subjects but whose continuation could only occur by
withholding care to other patients, again we would favour stop-
ping the study. Once the disruption has ended and ethical stan-
dards can again be met, research should be restarted as quickly
and feasibly as possible.
Given the nature of international collaborative partnerships,
consultation with local communities, collaborators and partici-
pants is essential to making the decision to stop research. The
goal of such partnerships is to ensure fair beneﬁts to local physi-
cians and communities and cannot be ignored when considering
this difﬁcult decision.17 If communities and participants feel
that continuation is undesirable and discussion continues to
reveal concerns of increased risk and uncertainty regarding
value of the research during disruptions in medical care, discon-
tinuing the research for this time would be included in the
physician-researcher’s responsibilities to these relationships.
Commitment and trust will continue to build relationships and
provide the groundwork for future research.
Additionally, continuing to conduct research during periods
of medical care disruption not only affects patients, but also
affects research. Lack of resources, medications and other stres-
ses often lead to difﬁculties in following research protocols.
When patients are not receiving optimal care, the validity of
research results is likely affected. This may place patients at
undue risk if the results from the study then are not useful or
generalisable. In this scenario when political events have dis-
rupted care and research in a way that undermines the scientiﬁc
validity of results, researchers must exercise caution when con-
sidering to continue providing study medicines or interventions
as it is difﬁcult to assess whether research is beneﬁting subjects
and it is potentially harmful to continue providing these medi-
cines when medical monitoring is not possible. As research has
the potential to be negatively affected ethically and scientiﬁcally
during times of medical care disruption, physician-researchers
must strongly consider the effects on their research and whether
continuation is worth pursuing while an already resource-
limited medical system is overwhelmed. Many research ques-
tions can and have been answered retrospectively during these
events, but careful consideration regarding necessity, feasibility
and risk-beneﬁt ratio must be given to continuing studies when
medical care is disrupted.14
When a study must be stopped because of a political disrup-
tion, discussion of post-trial obligations to subjects takes on new
meaning since beneﬁts to subjects are difﬁcult to assess, and
thus researchers should be cautious when considering to con-
tinue providing study medicines or interventions as mentioned
above. Researchers should continue to keep study subjects
informed and monitor their progress to the extent possible.18 22
ARGUMENT FOR CONTINUING RESEARCH
Conducting research is one of the most important means to
improve health.23 So, continuing to focus on research that has
the potential to improve the health of many more patients can
be defended on ethical and pragmatic grounds. The sooner a
study is completed, the sooner any results can be used to inform
care. Indeed, for some studies, discontinuing a study exposes
participants to unnecessary risk with no prospect of beneﬁt to
themselves. Continuing research honours the commitment that
researchers have made to research participants; breaking these
commitments might further damage conﬁdence and trust
towards medical research.24 Additionally, community engage-
ment identiﬁes and prioritises research with particular import-
ance to their society so continuation would continue to
promote beneﬁts for their local community. If communities and
participants believe this research was important to continue and
did not pose any increased risk, continuation would be import-
ant to promote trust between partnerships involved. Also,
whether research is clearly distinguished from clinical care or
seen as integrated with care, the impact of a disruption on one
should not in principle disrupt the other.
Conditions exist under which the study could be continued.
Research should continue if physician-researchers and commu-
nity members agree that continuation of research was the appro-
priate way to proceed, assuming critical evaluation of each
House DR, et al. J Med Ethics 2016;42:61–65. doi:10.1136/medethics-2013-101490 63
Viewpoint
party’s reasons to proceed. The ethics review committee that
approved the study is then made aware of the disruption of
care, and conﬁrms that the disruption will not adversely affect
the conditions of approval placed on the study, including
consent procedures, opportunities for withdrawal and availabil-
ity of study personnel. A study already approved by an ethics
committee that continues to meet ethical standards can continue
to be conducted.
These points make the case for permitting a study to continue
under conditions of politically caused medical disruption.
However, physician-researchers must carefully consider the
availability of existing resources, safety of human subjects and
reliability of results. For example, they may also have to deter-
mine how continuing a study might prevent a prior agreement
to provide care from being fulﬁlled.25 Given the increased risks
and vulnerability of the populations, studies should not be
started unless they can be assured of being completed.
ADDITIONAL CONSIDERATIONS
When considering whether to start, stop or continue research,
the type of research and research aims will likely inﬂuence this
decision. One may consider observational, low-risk studies less
burdensome and therefore, more permissible; however, the aims
of the study may be of little comparable importance to the
society in distress that it may seem unimportant to begin or con-
tinue until the situation has resolved or stabilised. On the other
hand, while interventional studies are quite burdensome, they
may be providing needed treatment for patients. Additionally, if
the aims of the study are of particular importance during times
of medical care disruption such as studies that address how to
optimise healthcare during times of disruption, it may shift the
balance of decision making in favour of starting or continuing
research. It will be important to consider the burden of these
studies on an already burdened population, engage local com-
munities regarding importance and expectations, and ensure
ethical standards are met.
CONCLUSION
Conducting research in developing countries offers unique chal-
lenges, especially during unforeseen and stressful situations
involving medical care disruption from political action. While
working in Kenya, these events have affected research and
caused physician-researchers to wonder how to proceed. With
increasing research in developing countries, more discussion
needs to occur regarding physician-researcher obligations during
times of medical care disruption. Whether circumstances
include political unrest, violence, physician strikes, etc, guide-
lines are needed to help physician-researchers prioritise ethical
obligations during already difﬁcult, stressful situations. We offer
the following recommendations regarding how to proceed with
research during medical care disruption in resource-constrained
settings.
Overall, research is extremely important to improve patient
care and should be encouraged, especially in resource-limited
countries. Research should always be conducted according to
recognised ethical standards for protection of human subjects
and promotion of scientiﬁc integrity with a speciﬁc focus on a
physician-researcher’s duty to provide care to patients. We
believe there is an ethical distinction between starting and con-
tinuing research. During periods of medical care disruption,
research that has already been started should continue when
possible. When research cannot meet these ethical standards, it
should not be started or, if already underway, should be ethically
stopped. Therefore, if the conditions in a country prevent or
seriously impede a researcher’s ability to meet ethical standards
required of the protocol, then a study that is underway should
be stopped or wound down in a manner consistent with patient
safety until ethical standards can be assured. If the cause of the
disruption ends, and it is possible to restart a previously stopped
study it should be restarted as quickly and feasibly as possible.
In countries where care disruption may be reasonably foreseen,
either from natural or human-caused factors, efforts should be
made to anticipate such situations and to include plans in the
protocol and consent form so that the institutional review board
is aware of the possibility as it undertakes its review that a study
might stop, and patients who are about to be enrolled would
know of this additional disclosure and risk of their participation
when they are reviewing consent materials. Studies that have
been approved but not yet started should not begin until the dis-
ruption has ended and ethical standards can again be assured.
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